In recent years the management of non-muscle-invasive bladder cancer has undergone radical changes. Intravesical Bacillus Calmette-Guérin (BCG) has long been established as the therapeutic standard ...
A review of studies including 20,000 patients with NMIBC highlights the need for individualized NMIBC management that balances oncologic control with QoL and patient-reported outcomes. Frequent ...
Chemoresection may be a minimally invasive option for recurrent Ta, intermediate-risk non-muscle-invasive bladder cancer (NMIBC).
Clinical utility of urine tumor DNA in bladder cancer patients. TheraP: 177Lu-PSMA-617 (LuPSMA) versus cabazitaxel in metastatic castration-resistant prostate cancer (mCRPC) progressing after ...
PARSIPPANY, N.J.--(BUSINESS WIRE)--Ferring Pharmaceuticals today announced the first patient in the United States with high-risk Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive bladder ...
PRINCETON, N.J., July 28, 2025 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (URGN), a biotech company dedicated to developing and commercializing innovative treatments for urothelial and specialty cancers, ...
Effect of digital Ki67-based risk modeling on prognostic precision in non–muscle-invasive bladder cancer and high-risk subsets in mixed-grade tumors. Prospective multicenter development and external ...
Neoadjuvant mitomycin C showed a favorable safety profile with mild to moderate side effects, including hematuria, dysuria, and itchy scalp. The trial did not show significant improvement in 12-month ...
Bladder cancer arises from the lining of the bladder, the organ that stores urine, and is one of the most common cancers in the United States. Most patients are diagnosed at an early stage called ...
A new study suggests that a urine-based biomarker test shows promise in forecasting bladder cancer treatment response, which ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results